{"items": "48", "sentiment_score_definition": "x <= -0.35: Bearish; -0.35 < x <= -0.15: Somewhat-Bearish; -0.15 < x < 0.15: Neutral; 0.15 <= x < 0.35: Somewhat_Bullish; x >= 0.35: Bullish", "relevance_score_definition": "0 < x <= 1, with a higher score indicating higher relevance.", "feed": [{"title": "Single Domain Antibody Platform Market to Reach US$ 86 Million by 2034, Expanding at a CAGR of 10.1% | Fact.MR Report", "url": "https://www.benzinga.com/pressreleases/24/12/g42312094/single-domain-antibody-platform-market-to-reach-us-86-million-by-2034-expanding-at-a-cagr-of-10-1-", "time_published": "20241204T123000", "authors": ["Globe Newswire"], "summary": "Rockville, MD, Dec. 04, 2024 ( GLOBE NEWSWIRE ) -- Increasing investments in healthcare research and development are leading to the increased adoption of single domain antibody platforms due to their key role in improving the efficacy of treatments.", "banner_image": "https://ml.globenewswire.com/Resource/Download/09c7b84a-4398-4495-9901-96a52fac0fdd/single-domain-antibody-platform-market.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Technology", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.323323, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "KANKF", "relevance_score": "0.038345", "ticker_sentiment_score": "0.056599", "ticker_sentiment_label": "Neutral"}, {"ticker": "OABI", "relevance_score": "0.038345", "ticker_sentiment_score": "0.046938", "ticker_sentiment_label": "Neutral"}]}, {"title": "OmniAb, Inc.  ( OABI )  Reports Q3 Loss, Lags Revenue Estimates", "url": "https://www.zacks.com/stock/news/2369269/omniab-inc-oabi-reports-q3-loss-lags-revenue-estimates", "time_published": "20241112T230521", "authors": ["Zacks Equity Research"], "summary": "OmniAb, Inc. (OABI) delivered earnings and revenue surprises of -14.29% and 52.95%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default159.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}, {"topic": "Earnings", "relevance_score": "0.999759"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.103235, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "OABI", "relevance_score": "0.402403", "ticker_sentiment_score": "0.044053", "ticker_sentiment_label": "Neutral"}, {"ticker": "OCUL", "relevance_score": "0.139669", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Vaccinex Provides Update on ActivMAb\u00ae Platform: Multiple Project Deals and Presentation at SITC", "url": "https://www.globenewswire.com/news-release/2024/11/07/2976690/34858/en/Vaccinex-Provides-Update-on-ActivMAb-Platform-Multiple-Project-Deals-and-Presentation-at-SITC.html", "time_published": "20241107T133000", "authors": ["Inc.", "Vaccinex"], "summary": "Partnerships will employ Vaccinex's ActivMAb\u00ae tech. Successful antibody discovery campaigns for cancer immunotherapy to be presented at SITC Nov 9, 2024.", "banner_image": "https://ml.globenewswire.com/Resource/Download/6a5e4bae-ba84-4fb3-a2ad-2cf268bfe3ba", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.495866"}], "overall_sentiment_score": -0.026572, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "DSSMY", "relevance_score": "0.038655", "ticker_sentiment_score": "0.050051", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABSI", "relevance_score": "0.038655", "ticker_sentiment_score": "-0.020642", "ticker_sentiment_label": "Neutral"}, {"ticker": "CHRS", "relevance_score": "0.038655", "ticker_sentiment_score": "-0.026621", "ticker_sentiment_label": "Neutral"}, {"ticker": "GRFS", "relevance_score": "0.038655", "ticker_sentiment_score": "-0.020642", "ticker_sentiment_label": "Neutral"}, {"ticker": "INCY", "relevance_score": "0.038655", "ticker_sentiment_score": "-0.020642", "ticker_sentiment_label": "Neutral"}, {"ticker": "OABI", "relevance_score": "0.038655", "ticker_sentiment_score": "-0.020642", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.038655", "ticker_sentiment_score": "0.058602", "ticker_sentiment_label": "Neutral"}, {"ticker": "VCNX", "relevance_score": "0.372077", "ticker_sentiment_score": "-0.037062", "ticker_sentiment_label": "Neutral"}]}, {"title": "Aurinia Pharmaceuticals  ( AUPH )  Q3 Earnings and Revenues Beat Estimates", "url": "https://www.zacks.com/stock/news/2366002/aurinia-pharmaceuticals-auph-q3-earnings-and-revenues-beat-estimates", "time_published": "20241107T124006", "authors": ["Zacks Equity Research"], "summary": "Aurinia (AUPH) delivered earnings and revenue surprises of 400% and 14.74%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default227.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}, {"topic": "Earnings", "relevance_score": "0.999981"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.141826, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "OABI", "relevance_score": "0.209365", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AUPH", "relevance_score": "0.140485", "ticker_sentiment_score": "0.035207", "ticker_sentiment_label": "Neutral"}]}, {"title": "The Benchmark Company Announces Upcoming Healthcare House Call VIRTUAL One-on-One Investor Conference", "url": "https://www.benzinga.com/pressreleases/24/05/g38645015/the-benchmark-company-announces-upcoming-healthcare-house-call-virtual-one-on-one-investor-confere", "time_published": "20240506T142100", "authors": ["Globe Newswire"], "summary": "NEW YORK, May 06, 2024 ( GLOBE NEWSWIRE ) -- The Benchmark Company is pleased to announce our upcoming Healthcare House Call VIRTUAL One-on-One Investor Conference happening on Tuesday & Wednesday, May 21st - 22nd, 2024.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}, {"topic": "Real Estate & Construction", "relevance_score": "0.333333"}, {"topic": "Technology", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.232721, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "HBIO", "relevance_score": "0.086245", "ticker_sentiment_score": "-0.047197", "ticker_sentiment_label": "Neutral"}, {"ticker": "CDXS", "relevance_score": "0.086245", "ticker_sentiment_score": "-0.047197", "ticker_sentiment_label": "Neutral"}, {"ticker": "HUMA", "relevance_score": "0.086245", "ticker_sentiment_score": "-0.047197", "ticker_sentiment_label": "Neutral"}, {"ticker": "EXAS", "relevance_score": "0.086245", "ticker_sentiment_score": "-0.047197", "ticker_sentiment_label": "Neutral"}, {"ticker": "MODD", "relevance_score": "0.086245", "ticker_sentiment_score": "-0.047197", "ticker_sentiment_label": "Neutral"}, {"ticker": "BLFS", "relevance_score": "0.086245", "ticker_sentiment_score": "-0.047197", "ticker_sentiment_label": "Neutral"}, {"ticker": "NNOX", "relevance_score": "0.086245", "ticker_sentiment_score": "-0.047197", "ticker_sentiment_label": "Neutral"}, {"ticker": "GNLX", "relevance_score": "0.086245", "ticker_sentiment_score": "-0.047197", "ticker_sentiment_label": "Neutral"}, {"ticker": "LGND", "relevance_score": "0.086245", "ticker_sentiment_score": "-0.047197", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABCL", "relevance_score": "0.086245", "ticker_sentiment_score": "-0.047197", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMED", "relevance_score": "0.086245", "ticker_sentiment_score": "-0.047197", "ticker_sentiment_label": "Neutral"}, {"ticker": "EBS", "relevance_score": "0.086245", "ticker_sentiment_score": "-0.047197", "ticker_sentiment_label": "Neutral"}, {"ticker": "RVPH", "relevance_score": "0.086245", "ticker_sentiment_score": "-0.047197", "ticker_sentiment_label": "Neutral"}, {"ticker": "HALO", "relevance_score": "0.086245", "ticker_sentiment_score": "-0.047197", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMN", "relevance_score": "0.086245", "ticker_sentiment_score": "-0.047197", "ticker_sentiment_label": "Neutral"}, {"ticker": "BLTE", "relevance_score": "0.086245", "ticker_sentiment_score": "-0.047197", "ticker_sentiment_label": "Neutral"}, {"ticker": "TLSI", "relevance_score": "0.086245", "ticker_sentiment_score": "-0.047197", "ticker_sentiment_label": "Neutral"}, {"ticker": "MDGEF", "relevance_score": "0.086245", "ticker_sentiment_score": "-0.047197", "ticker_sentiment_label": "Neutral"}, {"ticker": "ETON", "relevance_score": "0.086245", "ticker_sentiment_score": "-0.047197", "ticker_sentiment_label": "Neutral"}, {"ticker": "HCSG", "relevance_score": "0.254751", "ticker_sentiment_score": "-0.086133", "ticker_sentiment_label": "Neutral"}, {"ticker": "NUTX", "relevance_score": "0.086245", "ticker_sentiment_score": "-0.047197", "ticker_sentiment_label": "Neutral"}, {"ticker": "TECH", "relevance_score": "0.086245", "ticker_sentiment_score": "-0.047197", "ticker_sentiment_label": "Neutral"}, {"ticker": "MOVE", "relevance_score": "0.086245", "ticker_sentiment_score": "-0.047197", "ticker_sentiment_label": "Neutral"}, {"ticker": "CLNN", "relevance_score": "0.086245", "ticker_sentiment_score": "-0.047197", "ticker_sentiment_label": "Neutral"}, {"ticker": "RGEN", "relevance_score": "0.086245", "ticker_sentiment_score": "-0.047197", "ticker_sentiment_label": "Neutral"}, {"ticker": "QIPT", "relevance_score": "0.086245", "ticker_sentiment_score": "-0.047197", "ticker_sentiment_label": "Neutral"}, {"ticker": "SEM", "relevance_score": "0.086245", "ticker_sentiment_score": "-0.047197", "ticker_sentiment_label": "Neutral"}, {"ticker": "AUGX", "relevance_score": "0.086245", "ticker_sentiment_score": "-0.047197", "ticker_sentiment_label": "Neutral"}, {"ticker": "OABI", "relevance_score": "0.086245", "ticker_sentiment_score": "-0.047197", "ticker_sentiment_label": "Neutral"}, {"ticker": "SGRY", "relevance_score": "0.086245", "ticker_sentiment_score": "-0.047197", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRYPTO:NANO", "relevance_score": "0.086245", "ticker_sentiment_score": "-0.047197", "ticker_sentiment_label": "Neutral"}]}, {"title": "USANA Health Sciences  ( USNA )  Q1 Earnings and Revenues Top Estimates", "url": "https://www.zacks.com/stock/news/2265479/usana-health-sciences-usna-q1-earnings-and-revenues-top-estimates", "time_published": "20240430T215512", "authors": ["Zacks Equity Research"], "summary": "USANA Health (USNA) delivered earnings and revenue surprises of 24.64% and 2.03%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default317.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}, {"topic": "Earnings", "relevance_score": "0.999992"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.14843, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "HESG", "relevance_score": "0.069294", "ticker_sentiment_score": "0.076969", "ticker_sentiment_label": "Neutral"}, {"ticker": "OABI", "relevance_score": "0.205807", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "USNA", "relevance_score": "0.138066", "ticker_sentiment_score": "0.095608", "ticker_sentiment_label": "Neutral"}]}, {"title": "Over $1M Bet On OmniAb? Check Out These 3 Stocks Insiders Are Buying - Hallador Energy  ( NASDAQ:HNRG ) , OmniAb  ( NASDAQ:OABI ) ", "url": "https://www.benzinga.com/trading-ideas/long-ideas/24/03/37932523/over-1m-bet-on-omniab-check-out-these-3-stocks-insiders-are-buying", "time_published": "20240326T124044", "authors": ["Avi Kapoor"], "summary": "Although U.S. stocks closed lower on Monday, there were a few notable insider trades. When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock.", "banner_image": "https://cdn.benzinga.com/files/images/story/2024/03/26/image13.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Financial Markets", "relevance_score": "0.266143"}, {"topic": "Earnings", "relevance_score": "0.451494"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.108179"}, {"topic": "Energy & Transportation", "relevance_score": "0.333333"}, {"topic": "Technology", "relevance_score": "0.333333"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.27752, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "OABI", "relevance_score": "0.483888", "ticker_sentiment_score": "0.180833", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "HNRG", "relevance_score": "0.483888", "ticker_sentiment_score": "0.19896", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PPBI", "relevance_score": "0.483888", "ticker_sentiment_score": "0.426309", "ticker_sentiment_label": "Bullish"}]}, {"title": "Plus Therapeutics  ( PSTV )  Reports Q4 Loss, Tops Revenue Estimates", "url": "https://www.zacks.com/stock/news/2236280/plus-therapeutics-pstv-reports-q4-loss-tops-revenue-estimates", "time_published": "20240305T223503", "authors": ["Zacks Equity Research"], "summary": "Plus (PSTV) delivered earnings and revenue surprises of 10.26% and 4.21%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default291.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}, {"topic": "Earnings", "relevance_score": "0.999759"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.130706, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "PSTV", "relevance_score": "0.140485", "ticker_sentiment_score": "-0.064431", "ticker_sentiment_label": "Neutral"}, {"ticker": "OABI", "relevance_score": "0.209365", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Karyopharm Therapeutics  ( KPTI )  Reports Q4 Loss, Tops Revenue Estimates", "url": "https://www.zacks.com/stock/news/2233699/karyopharm-therapeutics-kpti-reports-q4-loss-tops-revenue-estimates", "time_published": "20240229T134005", "authors": ["Zacks Equity Research"], "summary": "Karyopharm Therapeutics (KPTI) delivered earnings and revenue surprises of -24.14% and 0.74%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default93.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}, {"topic": "Earnings", "relevance_score": "0.999759"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.119433, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "KPTI", "relevance_score": "0.402403", "ticker_sentiment_score": "0.101423", "ticker_sentiment_label": "Neutral"}, {"ticker": "OABI", "relevance_score": "0.208166", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "OmniAb, Inc.  ( OABI )  Soars 10.5%: Is Further Upside Left in the Stock?", "url": "https://www.zacks.com/stock/news/2233017/omniab-inc-oabi-soars-105-is-further-upside-left-in-the-stock", "time_published": "20240228T132700", "authors": ["Zacks Equity Research"], "summary": "OmniAb, Inc. (OABI) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default134.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.365926"}, {"topic": "Earnings", "relevance_score": "0.961735"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.167249, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "OABI", "relevance_score": "0.553595", "ticker_sentiment_score": "0.146344", "ticker_sentiment_label": "Neutral"}, {"ticker": "RIGL", "relevance_score": "0.352223", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Aclaris Therapeutics  ( ACRS )  Reports Q4 Loss, Tops Revenue Estimates", "url": "https://www.zacks.com/stock/news/2232371/aclaris-therapeutics-acrs-reports-q4-loss-tops-revenue-estimates", "time_published": "20240227T143502", "authors": ["Zacks Equity Research"], "summary": "Aclaris (ACRS) delivered earnings and revenue surprises of 18.92% and 344.14%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default185.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}, {"topic": "Earnings", "relevance_score": "0.999759"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.13071, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ACRS", "relevance_score": "0.140485", "ticker_sentiment_score": "-0.064431", "ticker_sentiment_label": "Neutral"}, {"ticker": "OABI", "relevance_score": "0.209365", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Zacks Industry Outlook Highlights Gilead Sciences, CRISPR Therapeutics, ACADIA Pharmaceuticals, Dynavax and Ligand Pharmaceuticals", "url": "https://www.zacks.com/stock/news/2188966/zacks-industry-outlook-highlights-gilead-sciences-crispr-therapeutics-acadia-pharmaceuticals-dynavax-and-ligand-pharmaceuticals", "time_published": "20231124T141000", "authors": ["Zacks Equity Research"], "summary": "Gilead Sciences, CRISPR Therapeutics, ACADIA Pharmaceuticals, Dynavax and Ligand Pharmaceuticals are part of the Zacks Industry Outlook article.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/c9/2325.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.980922"}, {"topic": "Earnings", "relevance_score": "0.947132"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.650727"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.225302, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "LGND", "relevance_score": "0.064104", "ticker_sentiment_score": "0.045096", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRSP", "relevance_score": "0.127795", "ticker_sentiment_score": "0.105904", "ticker_sentiment_label": "Neutral"}, {"ticker": "KDNY", "relevance_score": "0.021388", "ticker_sentiment_score": "0.138084", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.021388", "ticker_sentiment_score": "0.171316", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ACAD", "relevance_score": "0.064104", "ticker_sentiment_score": "0.045096", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.0854", "ticker_sentiment_score": "0.090184", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRTX", "relevance_score": "0.021388", "ticker_sentiment_score": "0.138084", "ticker_sentiment_label": "Neutral"}, {"ticker": "OABI", "relevance_score": "0.021388", "ticker_sentiment_score": "0.106821", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIIB", "relevance_score": "0.021388", "ticker_sentiment_score": "0.138084", "ticker_sentiment_label": "Neutral"}]}, {"title": "5 Biotech Stocks Likely to Thrive as Industry Prospects Look Bright", "url": "https://www.zacks.com/commentary/2187656/5-biotech-stocks-likely-to-thrive-as-industry-prospects-look-bright", "time_published": "20231122T130700", "authors": ["Ekta Bagri"], "summary": "New drug approvals and pipeline progress are likely to help maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and solid pipeline progress position GILD, CRSP, ACAD, DVAX and LGND well amid volatility.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/37/2337.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.87644"}, {"topic": "Earnings", "relevance_score": "0.947132"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.538269"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.227746, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "LGND", "relevance_score": "0.044634", "ticker_sentiment_score": "0.125054", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRSP", "relevance_score": "0.111281", "ticker_sentiment_score": "0.139072", "ticker_sentiment_label": "Neutral"}, {"ticker": "KDNY", "relevance_score": "0.022326", "ticker_sentiment_score": "0.061954", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.022326", "ticker_sentiment_score": "0.172148", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ACAD", "relevance_score": "0.044634", "ticker_sentiment_score": "0.125054", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.066908", "ticker_sentiment_score": "0.125817", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRTX", "relevance_score": "0.022326", "ticker_sentiment_score": "0.061954", "ticker_sentiment_label": "Neutral"}, {"ticker": "OABI", "relevance_score": "0.022326", "ticker_sentiment_score": "0.154669", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BIIB", "relevance_score": "0.022326", "ticker_sentiment_score": "0.061954", "ticker_sentiment_label": "Neutral"}]}, {"title": "OmniAb President and CEO Trades Company's Stock - OmniAb  ( NASDAQ:OABI ) ", "url": "https://www.benzinga.com/news/23/11/35751592/omniab-president-and-ceo-trades-companys-stock", "time_published": "20231113T150121", "authors": ["Benzinga Insights"], "summary": "Matthew W Foehr, President and CEO at OmniAb OABI, reported a large insider buy on November 13, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission on Monday showed that Foehr purchased 95,000 shares of OmniAb. The total transaction ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/insider_image_4.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Technology", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.967645"}], "overall_sentiment_score": 0.169121, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "OABI", "relevance_score": "0.483434", "ticker_sentiment_score": "0.271471", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Hillstream Enters into an Exclusive Option Agreement to Acquire a Clinical Stage Asset for Chronic Pruritis - Hillstream BioPharma  ( NASDAQ:HILS ) ", "url": "https://www.benzinga.com/pressreleases/23/09/g34447181/hillstream-enters-into-an-exclusive-option-agreement-to-acquire-a-clinical-stage-asset-for-chronic", "time_published": "20230911T155149", "authors": ["Globe Newswire"], "summary": "Anticipate completion of Phase 1 & Phase 2 clinical trials in chronic pruritis over the next approximately 12 months Seeking first approval in an orphan disease, PBC, for the treatment of moderate to severe chronic pruritis in which more than 70% of patients suffer from chronic pruritis", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "Mergers", "source_domain": "www.benzinga.com", "topics": [{"topic": "Technology", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.495866"}], "overall_sentiment_score": -0.09264, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "HILS", "relevance_score": "0.154703", "ticker_sentiment_score": "-0.01822", "ticker_sentiment_label": "Neutral"}, {"ticker": "OABI", "relevance_score": "0.077719", "ticker_sentiment_score": "-0.031071", "ticker_sentiment_label": "Neutral"}]}, {"title": "Hillstream BioPharma to Present at H.C. Wainwright 25th Annual Global Investment Conference September 11-13", "url": "https://www.globenewswire.com/news-release/2023/09/08/2740295/0/en/Hillstream-BioPharma-to-Present-at-H-C-Wainwright-25th-Annual-Global-Investment-Conference-September-11-13.html", "time_published": "20230908T183000", "authors": ["Inc.", "Hillstream BioPharma"], "summary": "BRIDGEWATER, N.J., Sept. 08, 2023 ( GLOBE NEWSWIRE ) -- Hillstream BioPharma, Inc. ( Nasdaq: HILS ) ( \"Hillstream\" or the \"Company\" ) , a biotechnology company developing therapeutic candidates targeting drug resistant and devastating cancers with immuno-oncology targeted novel biologics, today ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/72237a04-1dd7-41c8-b85a-36dcdc198f45", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Technology", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.495866"}], "overall_sentiment_score": -0.041365, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "HILS", "relevance_score": "0.204647", "ticker_sentiment_score": "0.136881", "ticker_sentiment_label": "Neutral"}, {"ticker": "OABI", "relevance_score": "0.137278", "ticker_sentiment_score": "0.166908", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Hillstream BioPharma to Present at H.C. Wainwright 25th Annual Global Investment Conference September 11-13 - Hillstream BioPharma  ( NASDAQ:HILS ) ", "url": "https://www.benzinga.com/pressreleases/23/09/g34368520/hillstream-biopharma-to-present-at-h-c-wainwright-25th-annual-global-investment-conference-septemb", "time_published": "20230908T183000", "authors": ["Globe Newswire"], "summary": "Management will present and hold virtual 1-on-1 meetings with institutional investors and analysts BRIDGEWATER, N.J., Sept. 08, 2023 ( GLOBE NEWSWIRE ) -- Hillstream BioPharma, Inc.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Technology", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.650727"}], "overall_sentiment_score": -0.048437, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "HILS", "relevance_score": "0.193207", "ticker_sentiment_score": "0.124622", "ticker_sentiment_label": "Neutral"}, {"ticker": "OABI", "relevance_score": "0.129516", "ticker_sentiment_score": "0.155786", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Hillstream BioPharma to Present at the Sidoti Micro-Cap Virtual Conference on August 16-17, 2023", "url": "https://www.globenewswire.com/news-release/2023/08/09/2721669/0/en/Hillstream-BioPharma-to-Present-at-the-Sidoti-Micro-Cap-Virtual-Conference-on-August-16-17-2023.html", "time_published": "20230809T124700", "authors": ["Hillstream BioPharma", "Inc."], "summary": "BRIDGEWATER, N.J., Aug. 09, 2023 ( GLOBE NEWSWIRE ) -- Hillstream BioPharma, Inc. ( Nasdaq: HILS ) ( \"Hillstream\" or the \"Company\" ) , a biotechnology company developing therapeutic candidates targeting drug resistant and devastating cancers using ferroptosis, an emerging new anti-cancer ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/72237a04-1dd7-41c8-b85a-36dcdc198f45", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Technology", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.495866"}], "overall_sentiment_score": 0.046281, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "HILS", "relevance_score": "0.160277", "ticker_sentiment_score": "0.0803", "ticker_sentiment_label": "Neutral"}, {"ticker": "OABI", "relevance_score": "0.21258", "ticker_sentiment_score": "0.190308", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Hillstream BioPharma to Present at the Sidoti Micro-Cap Virtual Conference on August 16-17, 2023 - Hillstream BioPharma  ( NASDAQ:HILS ) ", "url": "https://www.benzinga.com/pressreleases/23/08/g33665879/hillstream-biopharma-to-present-at-the-sidoti-micro-cap-virtual-conference-on-august-16-17-2023", "time_published": "20230809T124700", "authors": ["Globe Newswire"], "summary": "Management will present and hold virtual 1-on-1 meetings with institutional investors and analysts Company recently announced license and collaboration expansions for next-gen multispecific antibodies for solid tumors with lead HER2/HER3 program, HSB-3215, in collaboration with OmniAb, Inc. and ...", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Technology", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.650727"}], "overall_sentiment_score": 0.036483, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "HILS", "relevance_score": "0.156461", "ticker_sentiment_score": "0.076136", "ticker_sentiment_label": "Neutral"}, {"ticker": "OABI", "relevance_score": "0.207571", "ticker_sentiment_score": "0.195001", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Ligand  ( LGND )  to Post Q2 Earnings: What's in Store?", "url": "https://www.zacks.com/stock/news/2133134/ligand-lgnd-to-post-q2-earnings-whats-in-store", "time_published": "20230807T130200", "authors": ["Zacks Equity Research"], "summary": "Ligand's (LGND) second-quarter 2023 performance is likely to have been driven by rising royalty revenues on the back of higher growth in sales of drugs developed using its pelican platform.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/8b/382.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.99915"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.108546, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "KOD", "relevance_score": "0.1172", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "LGND", "relevance_score": "0.231884", "ticker_sentiment_score": "0.09543", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.1172", "ticker_sentiment_score": "0.161884", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BLUE", "relevance_score": "0.1172", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "OABI", "relevance_score": "0.058759", "ticker_sentiment_score": "-0.028035", "ticker_sentiment_label": "Neutral"}]}, {"title": "Cadence Design and Ligand have been highlighted as Zacks Bull and Bear of the Day", "url": "https://www.zacks.com/stock/news/2125288/cadence-design-and-ligand-have-been-highlighted-as-zacks-bull-and-bear-of-the-day", "time_published": "20230721T130400", "authors": ["Zacks Investment Research"], "summary": "Chicago, IL - July 21, 2023 - Zacks Equity Research shares Cadence Design Systems ( CDNS Quick QuoteCDNS - ) as the Bull of the Day and Ligand Pharmaceuticals ( LGND Quick QuoteLGND - ) as the Bear of the Day.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/71/144.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}, {"topic": "Finance", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "0.316726"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.360215"}], "overall_sentiment_score": 0.154637, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MSFT", "relevance_score": "0.016227", "ticker_sentiment_score": "0.085657", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVDA", "relevance_score": "0.285711", "ticker_sentiment_score": "0.131301", "ticker_sentiment_label": "Neutral"}, {"ticker": "LGND", "relevance_score": "0.048654", "ticker_sentiment_score": "0.041463", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.048654", "ticker_sentiment_score": "0.008936", "ticker_sentiment_label": "Neutral"}, {"ticker": "WFC", "relevance_score": "0.016227", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNPS", "relevance_score": "0.064841", "ticker_sentiment_score": "0.033057", "ticker_sentiment_label": "Neutral"}, {"ticker": "CDNS", "relevance_score": "0.113215", "ticker_sentiment_score": "0.111768", "ticker_sentiment_label": "Neutral"}, {"ticker": "ERJ", "relevance_score": "0.081001", "ticker_sentiment_score": "0.022497", "ticker_sentiment_label": "Neutral"}, {"ticker": "LHX", "relevance_score": "0.064841", "ticker_sentiment_score": "0.024012", "ticker_sentiment_label": "Neutral"}, {"ticker": "OABI", "relevance_score": "0.048654", "ticker_sentiment_score": "0.048395", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.016227", "ticker_sentiment_score": "0.198649", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BA", "relevance_score": "0.192822", "ticker_sentiment_score": "0.193193", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Bear of the Day: Ligand Pharmaceuticals  ( LGND ) ", "url": "https://www.zacks.com/commentary/2124960/bear-of-the-day-ligand-pharmaceuticals-lgnd", "time_published": "20230721T102000", "authors": ["Kevin Cook"], "summary": "Ligand is an innovative Bio-Pharma M&A royalty-generator, but the model is volatile ...", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/88/898.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Earnings", "relevance_score": "0.538269"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.360215"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.0497, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "OABI", "relevance_score": "0.344074", "ticker_sentiment_score": "0.116692", "ticker_sentiment_label": "Neutral"}, {"ticker": "LGND", "relevance_score": "0.233556", "ticker_sentiment_score": "0.046212", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.118064", "ticker_sentiment_score": "0.251012", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "5 Biotech Stocks to Buy as Industry Prospects for 2H23 Look Good", "url": "https://www.zacks.com/commentary/2107444/5-biotech-stocks-to-buy-as-industry-prospects-for-2h23-look-good", "time_published": "20230613T133000", "authors": ["Zacks Investment Research"], "summary": "New drug approvals and pipeline progress are likely to help maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and a solid pipeline progress position PCVX, PTGX, LGND, MESO and PBYI well amid volatility.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default306.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.796627"}, {"topic": "Earnings", "relevance_score": "0.818451"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.451494"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.182379, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MESO", "relevance_score": "0.138464", "ticker_sentiment_score": "-0.020259", "ticker_sentiment_label": "Neutral"}, {"ticker": "PCVX", "relevance_score": "0.092569", "ticker_sentiment_score": "0.047862", "ticker_sentiment_label": "Neutral"}, {"ticker": "PTGX", "relevance_score": "0.069495", "ticker_sentiment_score": "0.147221", "ticker_sentiment_label": "Neutral"}, {"ticker": "LGND", "relevance_score": "0.046363", "ticker_sentiment_score": "-0.017913", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.069495", "ticker_sentiment_score": "0.228442", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "KDNY", "relevance_score": "0.023191", "ticker_sentiment_score": "0.069874", "ticker_sentiment_label": "Neutral"}, {"ticker": "PBYI", "relevance_score": "0.092569", "ticker_sentiment_score": "0.016105", "ticker_sentiment_label": "Neutral"}, {"ticker": "SGEN", "relevance_score": "0.023191", "ticker_sentiment_score": "0.069874", "ticker_sentiment_label": "Neutral"}, {"ticker": "OABI", "relevance_score": "0.023191", "ticker_sentiment_score": "0.192438", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PFE", "relevance_score": "0.023191", "ticker_sentiment_score": "0.069874", "ticker_sentiment_label": "Neutral"}]}, {"title": "7 Hot Penny Stocks To Buy In May According To Insiders", "url": "https://pennystocks.com/featured/2023/05/16/7-hot-penny-stocks-to-buy-in-may-according-to-insiders/", "time_published": "20230516T160040", "authors": ["J. Samuel"], "summary": "Penny stocks are typically sought after in hopes of discovering hidden potential. In this article, we look at recent insider buying and see if there are any current or upcoming events worth noting to prompt insider action.", "banner_image": "https://pennystocks.com/wp-content/uploads/2023/05/penny-stocks-trading-insider-trades.jpg", "source": "PennyStocks.com", "category_within_source": "n/a", "source_domain": "pennystocks.com", "topics": [{"topic": "Financial Markets", "relevance_score": "0.998333"}, {"topic": "Earnings", "relevance_score": "0.976913"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.158519"}, {"topic": "Technology", "relevance_score": "1.0"}], "overall_sentiment_score": 0.289662, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "SOND", "relevance_score": "0.067727", "ticker_sentiment_score": "0.068329", "ticker_sentiment_label": "Neutral"}, {"ticker": "GETR", "relevance_score": "0.168255", "ticker_sentiment_score": "0.120688", "ticker_sentiment_label": "Neutral"}, {"ticker": "HYREQ", "relevance_score": "0.067727", "ticker_sentiment_score": "0.087436", "ticker_sentiment_label": "Neutral"}, {"ticker": "OABI", "relevance_score": "0.134968", "ticker_sentiment_score": "0.06996", "ticker_sentiment_label": "Neutral"}]}, {"title": "Stratasys, Navitas Semiconductor, United Insurance And Other Big Stocks Moving Higher On Tuesday - Archer Aviation  ( NYSE:ACHR ) , Advantage Solutions  ( NASDAQ:ADV ) ", "url": "https://www.benzinga.com/news/23/05/32425165/stratasys-navitas-semiconductor-united-insurance-and-other-big-stocks-moving-higher-on-tuesday", "time_published": "20230516T150320", "authors": ["Lisa Levin"], "summary": "Applied Digital Corporation APLD jumped 44.6% to $4.94 after the company announced that its recently launched AI Cloud Service has secured its first major AI customer with an agreement worth up to $180 million over a 24-month period.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/05/16/stratasys_-_logo.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.2"}, {"topic": "Technology", "relevance_score": "0.2"}, {"topic": "Finance", "relevance_score": "0.2"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}, {"topic": "Manufacturing", "relevance_score": "0.2"}, {"topic": "Earnings", "relevance_score": "0.451494"}, {"topic": "Real Estate & Construction", "relevance_score": "0.2"}], "overall_sentiment_score": 0.430394, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "CABA", "relevance_score": "0.371523", "ticker_sentiment_score": "0.244767", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NVTS", "relevance_score": "0.252987", "ticker_sentiment_score": "0.422796", "ticker_sentiment_label": "Bullish"}, {"ticker": "CNDT", "relevance_score": "0.252987", "ticker_sentiment_score": "0.455179", "ticker_sentiment_label": "Bullish"}, {"ticker": "PLMR", "relevance_score": "0.252987", "ticker_sentiment_score": "0.343498", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PX", "relevance_score": "0.252987", "ticker_sentiment_score": "0.60267", "ticker_sentiment_label": "Bullish"}, {"ticker": "UIHC", "relevance_score": "0.252987", "ticker_sentiment_score": "0.333085", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ACHR", "relevance_score": "0.252987", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ADV", "relevance_score": "0.371523", "ticker_sentiment_score": "0.756856", "ticker_sentiment_label": "Bullish"}, {"ticker": "APLD", "relevance_score": "0.252987", "ticker_sentiment_score": "0.326677", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NBTX", "relevance_score": "0.371523", "ticker_sentiment_score": "0.210637", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SSYS", "relevance_score": "0.252987", "ticker_sentiment_score": "0.483554", "ticker_sentiment_label": "Bullish"}, {"ticker": "VTSI", "relevance_score": "0.252987", "ticker_sentiment_score": "0.503572", "ticker_sentiment_label": "Bullish"}, {"ticker": "OABI", "relevance_score": "0.371523", "ticker_sentiment_score": "0.49651", "ticker_sentiment_label": "Bullish"}]}, {"title": "$1.5M Bet On This Healthcare Stock? Check Out These 3 Penny Stocks Insiders Are Aggressively Buying - Citizens  ( NYSE:CIA ) , OmniAb  ( NASDAQ:OABI ) ", "url": "https://www.benzinga.com/trading-ideas/long-ideas/23/05/32418648/1-5m-bet-on-this-healthcare-stock-check-out-these-3-penny-stocks-insiders-are-aggressive", "time_published": "20230516T114904", "authors": ["Lisa Levin"], "summary": "The Dow Jones closed higher on Monday after recording losses last week. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/05/16/image16.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Financial Markets", "relevance_score": "0.161647"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.161647"}, {"topic": "Technology", "relevance_score": "0.5"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.208433, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "OABI", "relevance_score": "0.587597", "ticker_sentiment_score": "0.224612", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CIA", "relevance_score": "0.377142", "ticker_sentiment_score": "0.335829", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SONN", "relevance_score": "0.587597", "ticker_sentiment_score": "0.2723", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Ligand  ( LGND )  Up 3% on Raised '23 View, Beats on Q1 Earnings", "url": "https://www.zacks.com/stock/news/2091743/ligand-lgnd-up-3-on-raised-23-view-beats-on-q1-earnings", "time_published": "20230508T163200", "authors": ["Zacks Investment Research"], "summary": "Ligand Pharmaceuticals (LGND) announces better-than-expected results in first-quarter 2023. Management raises 2023 financial outlook.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/21/594.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}, {"topic": "Earnings", "relevance_score": "0.891286"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.149081, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "TVTX", "relevance_score": "0.141448", "ticker_sentiment_score": "0.027332", "ticker_sentiment_label": "Neutral"}, {"ticker": "VKTX", "relevance_score": "0.233556", "ticker_sentiment_score": "0.196823", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "LGND", "relevance_score": "0.233556", "ticker_sentiment_score": "0.256726", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "OABI", "relevance_score": "0.233556", "ticker_sentiment_score": "-0.078701", "ticker_sentiment_label": "Neutral"}]}, {"title": "Here's How Much a $1000 Investment in Ligand Pharmaceuticals Made 10 Years Ago Would Be Worth Today", "url": "https://www.zacks.com/stock/news/2080898/heres-how-much-a-1000-investment-in-ligand-pharmaceuticals-made-10-years-ago-would-be-worth-today", "time_published": "20230419T123004", "authors": ["Zacks Investment Research"], "summary": "Holding on to popular or trending stocks for the long-term can make your portfolio a winner.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default32.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.87644"}, {"topic": "Earnings", "relevance_score": "0.495866"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.538269"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.211905, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "OABI", "relevance_score": "0.291644", "ticker_sentiment_score": "0.16318", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "LGND", "relevance_score": "0.34648", "ticker_sentiment_score": "0.254944", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PFE", "relevance_score": "0.059636", "ticker_sentiment_score": "0.064017", "ticker_sentiment_label": "Neutral"}]}, {"title": "Here's Why You Should Add Ligand  ( LGND )  Stock to Your Portfolio", "url": "https://www.zacks.com/stock/news/2075611/heres-why-you-should-add-ligand-lgnd-stock-to-your-portfolio", "time_published": "20230406T142300", "authors": ["Zacks Investment Research"], "summary": "Ligand's (LGND) proprietary platforms enable it to form partnerships with several leading drug companies, providing it with funds through milestone and royalty payments.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/21/594.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}, {"topic": "Earnings", "relevance_score": "0.996718"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.234088, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.103554", "ticker_sentiment_score": "0.156676", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "OABI", "relevance_score": "0.051886", "ticker_sentiment_score": "0.099527", "ticker_sentiment_label": "Neutral"}, {"ticker": "LGND", "relevance_score": "0.255106", "ticker_sentiment_score": "0.271177", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Do Options Traders Know Something About OmniAb  ( OABI )  Stock We Don't?", "url": "https://www.zacks.com/stock/news/2072881/do-options-traders-know-something-about-omniab-oabi-stock-we-dont", "time_published": "20230331T124000", "authors": ["Zacks Investment Research"], "summary": "Investors need to pay close attention to OmniAb (OABI) stock based on the movements in the options market lately.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/85/388.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Technology", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}], "overall_sentiment_score": 0.078602, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "OABI", "relevance_score": "0.595343", "ticker_sentiment_score": "0.12607", "ticker_sentiment_label": "Neutral"}]}, {"title": "The Increasing Prevalence Of Cancer Is Among The Major Growth Drivers For The Bi-Specific MAbs Market - By The Business Research Company", "url": "https://www.prnewswire.com/news-releases/the-increasing-prevalence-of-cancer-is-among-the-major-growth-drivers-for-the-bi-specific-mabs-market--by-the-business-research-company-301785565.html", "time_published": "20230330T104000", "authors": ["The Business Research Company"], "summary": "The Increasing Prevalence Of Cancer Is Among The Major Growth ... PR ...", "banner_image": "https://mma.prnewswire.com/media/1751581/tbrc_logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Technology", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.074053, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "OABI", "relevance_score": "0.068698", "ticker_sentiment_score": "0.081378", "ticker_sentiment_label": "Neutral"}]}, {"title": "Zacks Industry Outlook Highlights CRISPR Therapeutics, Ligand Pharmaceuticals, Theseus Pharmaceuticals and Kala Pharmaceuticals", "url": "https://www.zacks.com/stock/news/2068930/zacks-industry-outlook-highlights-crispr-therapeutics-ligand-pharmaceuticals-theseus-pharmaceuticals-and-kala-pharmaceuticals", "time_published": "20230322T113700", "authors": ["Zacks Investment Research"], "summary": "CRISPR Therapeutics, Ligand Pharmaceuticals, Theseus Pharmaceuticals and Kala Pharmaceuticals are part of the Zacks Industry Outlook article.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/67/1932.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.962106"}, {"topic": "Earnings", "relevance_score": "0.744043"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.451494"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.186831, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "LGND", "relevance_score": "0.07793", "ticker_sentiment_score": "0.018332", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRSP", "relevance_score": "0.07793", "ticker_sentiment_score": "0.018332", "ticker_sentiment_label": "Neutral"}, {"ticker": "HZNP", "relevance_score": "0.026013", "ticker_sentiment_score": "0.017488", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALC", "relevance_score": "0.026013", "ticker_sentiment_score": "0.148156", "ticker_sentiment_label": "Neutral"}, {"ticker": "KALA", "relevance_score": "0.07793", "ticker_sentiment_score": "0.018332", "ticker_sentiment_label": "Neutral"}, {"ticker": "SGEN", "relevance_score": "0.026013", "ticker_sentiment_score": "0.017488", "ticker_sentiment_label": "Neutral"}, {"ticker": "OABI", "relevance_score": "0.026013", "ticker_sentiment_score": "0.19474", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "THRX", "relevance_score": "0.07793", "ticker_sentiment_score": "0.018332", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.026013", "ticker_sentiment_score": "0.017488", "ticker_sentiment_label": "Neutral"}]}, {"title": "4 Biotech Stocks to Consider for Your Portfolio in 2023", "url": "https://www.zacks.com/commentary/2068484/4-biotech-stocks-to-consider-for-your-portfolio-in-2023", "time_published": "20230321T153200", "authors": ["Zacks Investment Research"], "summary": "New drug approvals and pipeline progress should maintain the momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and a solid pipeline progress position CRSP, LGND, THRX and KALA well amid volatility.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/21/594.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.796627"}, {"topic": "Earnings", "relevance_score": "0.744043"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.451494"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.186941, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "LGND", "relevance_score": "0.053749", "ticker_sentiment_score": "0.060037", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRSP", "relevance_score": "0.053749", "ticker_sentiment_score": "0.060037", "ticker_sentiment_label": "Neutral"}, {"ticker": "HZNP", "relevance_score": "0.02689", "ticker_sentiment_score": "0.098044", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALC", "relevance_score": "0.02689", "ticker_sentiment_score": "0.148727", "ticker_sentiment_label": "Neutral"}, {"ticker": "KALA", "relevance_score": "0.080548", "ticker_sentiment_score": "0.060194", "ticker_sentiment_label": "Neutral"}, {"ticker": "SGEN", "relevance_score": "0.02689", "ticker_sentiment_score": "0.098044", "ticker_sentiment_label": "Neutral"}, {"ticker": "OABI", "relevance_score": "0.02689", "ticker_sentiment_score": "0.195413", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "THRX", "relevance_score": "0.080548", "ticker_sentiment_score": "0.060194", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.02689", "ticker_sentiment_score": "0.098044", "ticker_sentiment_label": "Neutral"}]}, {"title": "Ligand's  ( LGND )  Q4 Sales & Earnings Top, View Raised, Stock Up", "url": "https://www.zacks.com/stock/news/2057948/ligands-lgnd-q4-sales-earnings-top-view-raised-stock-up", "time_published": "20230223T124900", "authors": ["Zacks Investment Research"], "summary": "Ligand Pharmaceuticals (LGND) announces better-than-expected results in fourth-quarter 2022. Stock is up in the after-market hours in response to the news. Management raises 2023 financial outlook.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/ba/1149.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}, {"topic": "Earnings", "relevance_score": "0.99246"}, {"topic": "Energy & Transportation", "relevance_score": "0.333333"}, {"topic": "Technology", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.123944, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "TVTX", "relevance_score": "0.088964", "ticker_sentiment_score": "0.038758", "ticker_sentiment_label": "Neutral"}, {"ticker": "LGND", "relevance_score": "0.262522", "ticker_sentiment_score": "0.152409", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JAZZ", "relevance_score": "0.088964", "ticker_sentiment_score": "0.080588", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRNA", "relevance_score": "0.044551", "ticker_sentiment_score": "-0.052832", "ticker_sentiment_label": "Neutral"}, {"ticker": "AVA", "relevance_score": "0.044551", "ticker_sentiment_score": "0.097232", "ticker_sentiment_label": "Neutral"}, {"ticker": "NOVN", "relevance_score": "0.044551", "ticker_sentiment_score": "0.240843", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "OABI", "relevance_score": "0.262522", "ticker_sentiment_score": "0.09211", "ticker_sentiment_label": "Neutral"}]}, {"title": "5 Penny Stocks With Explosive Price Targets & Buy Ratings From Analysts", "url": "https://pennystocks.com/featured/2022/12/27/5-penny-stocks-explosive-price-targets-buy-ratings-analysts/", "time_published": "20221227T185237", "authors": ["J. Samuel"], "summary": "Penny Stocks To Buy According To Analysts As the stock market continues to become more and more unpredictable, it's increasingly important for traders to use every available tool. Whether you're trading penny stocks or higher-priced shares, one of those tools is analyst insight.", "banner_image": "https://pennystocks.com/wp-content/uploads/2022/01/best-penny-stocks-to-buy-right-now-analysts-insiders.jpg", "source": "PennyStocks.com", "category_within_source": "n/a", "source_domain": "pennystocks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Earnings", "relevance_score": "0.310843"}, {"topic": "Energy & Transportation", "relevance_score": "0.333333"}, {"topic": "Technology", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.149994, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "TCON", "relevance_score": "0.065506", "ticker_sentiment_score": "0.093539", "ticker_sentiment_label": "Neutral"}, {"ticker": "LGND", "relevance_score": "0.065506", "ticker_sentiment_score": "-0.009036", "ticker_sentiment_label": "Neutral"}, {"ticker": "CKPT", "relevance_score": "0.065506", "ticker_sentiment_score": "0.020128", "ticker_sentiment_label": "Neutral"}, {"ticker": "AVA", "relevance_score": "0.032781", "ticker_sentiment_score": "-0.008567", "ticker_sentiment_label": "Neutral"}, {"ticker": "OABI", "relevance_score": "0.162802", "ticker_sentiment_score": "0.103187", "ticker_sentiment_label": "Neutral"}]}, {"title": "Some 'Transgenic Animal Platforms Are More Than Equal,' Analyst Initiating Coverage On OmniAb Says - OmniAb  ( NASDAQ:OABI ) ", "url": "https://www.benzinga.com/analyst-ratings/analyst-color/22/12/30111844/some-transgenic-animal-platforms-are-more-than-equal-analyst-initiating-coverage-on", "time_published": "20221216T173912", "authors": ["Vandana Singh"], "summary": "Credit Suisse initiated coverage on OmniAb Inc OABI with an Outperform rating and a price target of $13. The company is spun off of Ligand Pharmaceuticals Inc's LGND antibody discovery business.", "banner_image": "https://cdn.benzinga.com/files/images/story/2022/12/16/oabi_logo_light__61faa132e07c86aa87fdedf3269e527f.png?optimize=medium&dpr=2&auto=webp&width=3840", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.158519"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.202743, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "OABI", "relevance_score": "0.647749", "ticker_sentiment_score": "0.409138", "ticker_sentiment_label": "Bullish"}, {"ticker": "LGND", "relevance_score": "0.358152", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Ligand Pharma Issues Mixed Guidance For FY23 - Ligand Pharmaceuticals  ( NASDAQ:LGND ) ", "url": "https://www.benzinga.com/general/biotech/22/12/30062561/ligand-pharma-issues-mixed-guidance-for-fy23", "time_published": "20221213T194726", "authors": ["Vandana Singh"], "summary": "At its Investor and Analyst Day event, Ligand Pharmaceuticals Incorporated LGND provided an overview of Ligand's corporate structure and business following the successful spin-off of its OmniAb antibody discovery business. Management also introduced 2023 financial guidance.", "banner_image": "https://cdn.benzinga.com/files/images/story/2022/12/13/logo_light__b69d6d372d65240abf487ba5457c0962.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.158519"}, {"topic": "Earnings", "relevance_score": "0.266143"}, {"topic": "Energy & Transportation", "relevance_score": "0.333333"}, {"topic": "Technology", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.165366, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AVA", "relevance_score": "0.18967", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "OABI", "relevance_score": "0.368773", "ticker_sentiment_score": "0.231387", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "LGND", "relevance_score": "0.528475", "ticker_sentiment_score": "0.398316", "ticker_sentiment_label": "Bullish"}]}, {"title": "Penny Stocks To Buy Now? 3 Low Float Stocks Under $1 To Watch", "url": "https://pennystocks.com/featured/2022/12/09/penny-stocks-to-buy-now-3-low-float-stocks-under-1-to-watch/", "time_published": "20221209T174522", "authors": ["J. Samuel"], "summary": "One of the exciting things about penny stocks is that they can break out big even if the stock market is down. On top of that, it doesn't take any significant catalyst to spark a rally. Many catalysts that trigger a retail trading frenzy have less to do with companies directly and more to do with ...", "banner_image": null, "source": "PennyStocks.com", "category_within_source": "n/a", "source_domain": "pennystocks.com", "topics": [{"topic": "Technology", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.999999"}], "overall_sentiment_score": 0.162531, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GOOG", "relevance_score": "0.03443", "ticker_sentiment_score": "0.406787", "ticker_sentiment_label": "Bullish"}, {"ticker": "WLDS", "relevance_score": "0.103035", "ticker_sentiment_score": "0.040994", "ticker_sentiment_label": "Neutral"}, {"ticker": "OABI", "relevance_score": "0.103035", "ticker_sentiment_score": "0.13862", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMAM", "relevance_score": "0.302346", "ticker_sentiment_score": "0.040432", "ticker_sentiment_label": "Neutral"}]}, {"title": "Ligand  ( LGND )  Down 3% Since Last Earnings Report: Can It Rebound?", "url": "https://www.zacks.com/stock/news/2026397/ligand-lgnd-down-3-since-last-earnings-report-can-it-rebound", "time_published": "20221207T163032", "authors": ["Zacks Investment Research"], "summary": "Ligand (LGND) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default9.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.365926"}, {"topic": "Earnings", "relevance_score": "0.998917"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.109961, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "INCY", "relevance_score": "0.219809", "ticker_sentiment_score": "0.026912", "ticker_sentiment_label": "Neutral"}, {"ticker": "OABI", "relevance_score": "0.110973", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "LGND", "relevance_score": "0.055621", "ticker_sentiment_score": "-0.004003", "ticker_sentiment_label": "Neutral"}]}, {"title": "$1 Million Bet On OmniAb? Check Out These 3 Penny Stocks Insiders Are Buying - DiaMedica Therapeutics  ( NASDAQ:DMAC ) , Ballantyne Strong  ( AMEX:BTN ) ", "url": "https://www.benzinga.com/trading-ideas/long-ideas/22/12/29938748/1-million-bet-on-omniab-check-out-these-3-penny-stocks-insiders-are-buying", "time_published": "20221202T134337", "authors": ["Lisa Levin"], "summary": "The Dow Jones closed lower by around 200 points on Thursday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects.", "banner_image": "https://cdn.benzinga.com/files/images/story/2022/12/02/image18.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.108179"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.287809, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "OABI", "relevance_score": "0.544495", "ticker_sentiment_score": "0.367735", "ticker_sentiment_label": "Bullish"}, {"ticker": "DMAC", "relevance_score": "0.544495", "ticker_sentiment_score": "0.264775", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Hillstream BioPharma Announces Development of Proprietary Targeted Biologics, Knob Quatrabodies\u2122  ( HSB-1940 )  against PD-1, by combining Quatramers\u2122 with OmniAb's Picobodies\u2122, via a Collaboration Agreement, against Novel, Unreachable and Undruggable Epitopes in High Value Validated Targets", "url": "https://www.globenewswire.com/news-release/2022/12/01/2566005/0/en/Hillstream-BioPharma-Announces-Development-of-Proprietary-Targeted-Biologics-Knob-Quatrabodies-HSB-1940-against-PD-1-by-combining-Quatramers-with-OmniAb-s-Picobodies-via-a-Collabor.html", "time_published": "20221201T134700", "authors": ["Hillstream BioPharma", "Inc."], "summary": "Collaboration allows Hillstream to enter the rapidly growing Immuno-oncology therapeutics market ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/72237a04-1dd7-41c8-b85a-36dcdc198f45?size=1", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Technology", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.310843"}], "overall_sentiment_score": 0.084394, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "HILS", "relevance_score": "0.083541", "ticker_sentiment_score": "-0.03491", "ticker_sentiment_label": "Neutral"}, {"ticker": "OABI", "relevance_score": "0.299478", "ticker_sentiment_score": "0.218793", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "3 Penny Stocks To Buy According To Analysts, Targets Up To 317%", "url": "https://pennystocks.com/featured/2022/11/29/3-penny-stocks-to-buy-according-to-analysts-targets-up-to-317/", "time_published": "20221129T155839", "authors": ["J. Samuel"], "summary": "3 Hot Penny Stocks To Buy For Under $3, Worth It? Penny stocks are some of the most volatile assets in the stock market today. But is the risk worth the reward? That's something traders grapple with daily.", "banner_image": "https://pennystocks.com/wp-content/uploads/2021/12/best-penny-stocks-to-buy-now-according-to-analysts.jpg", "source": "PennyStocks.com", "category_within_source": "n/a", "source_domain": "pennystocks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Energy & Transportation", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}, {"topic": "Economy - Monetary", "relevance_score": "0.310843"}, {"topic": "Financial Markets", "relevance_score": "0.999941"}, {"topic": "Earnings", "relevance_score": "0.938793"}, {"topic": "Real Estate & Construction", "relevance_score": "0.25"}], "overall_sentiment_score": 0.235827, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GOOG", "relevance_score": "0.038592", "ticker_sentiment_score": "0.409282", "ticker_sentiment_label": "Bullish"}, {"ticker": "LGND", "relevance_score": "0.077094", "ticker_sentiment_score": "-0.059463", "ticker_sentiment_label": "Neutral"}, {"ticker": "AVA", "relevance_score": "0.038592", "ticker_sentiment_score": "-0.057023", "ticker_sentiment_label": "Neutral"}, {"ticker": "OABI", "relevance_score": "0.19117", "ticker_sentiment_score": "0.132878", "ticker_sentiment_label": "Neutral"}, {"ticker": "BFLY", "relevance_score": "0.077094", "ticker_sentiment_score": "0.072236", "ticker_sentiment_label": "Neutral"}, {"ticker": "FOREX:USD", "relevance_score": "0.038592", "ticker_sentiment_score": "0.048372", "ticker_sentiment_label": "Neutral"}]}, {"title": "Nasdaq Down 60 Points; Alibaba Posts Upbeat Q2 Earnings - Alibaba Group Holding  ( NYSE:BABA ) , Ardelyx  ( NASDAQ:ARDX ) ", "url": "https://www.benzinga.com/news/earnings/22/11/29773565/nasdaq-down-60-points-alibaba-posts-upbeat-q2-earnings", "time_published": "20221117T193202", "authors": ["Lisa Levin"], "summary": "U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite dropping around 60 points on Thursday. The Dow traded down 0.18% to 33,491.86 while the NASDAQ fell 0.54% to 11,123.49. The S&P 500 also fell, dropping, 0.56% to 3,936.57.", "banner_image": "https://cdn.benzinga.com/files/images/story/2022/11/17/image37.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.2"}, {"topic": "Technology", "relevance_score": "0.2"}, {"topic": "Finance", "relevance_score": "0.2"}, {"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "IPO", "relevance_score": "0.310843"}, {"topic": "Economy - Fiscal", "relevance_score": "0.158519"}, {"topic": "Retail & Wholesale", "relevance_score": "0.2"}, {"topic": "Financial Markets", "relevance_score": "0.87644"}, {"topic": "Manufacturing", "relevance_score": "0.2"}, {"topic": "Earnings", "relevance_score": "0.857896"}], "overall_sentiment_score": -0.019484, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "BABA", "relevance_score": "0.162437", "ticker_sentiment_score": "0.183883", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ELVT", "relevance_score": "0.108712", "ticker_sentiment_score": "0.309671", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "TNYA", "relevance_score": "0.108712", "ticker_sentiment_score": "0.209235", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "EDIT", "relevance_score": "0.162437", "ticker_sentiment_score": "0.196673", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ARDX", "relevance_score": "0.215415", "ticker_sentiment_score": "0.30917", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DZSI", "relevance_score": "0.108712", "ticker_sentiment_score": "0.094821", "ticker_sentiment_label": "Neutral"}, {"ticker": "BBWI", "relevance_score": "0.108712", "ticker_sentiment_score": "0.354808", "ticker_sentiment_label": "Bullish"}, {"ticker": "OABI", "relevance_score": "0.108712", "ticker_sentiment_score": "0.4542", "ticker_sentiment_label": "Bullish"}]}, {"title": "Best Penny Stocks To Buy Now That CPI Is Out? 4 To Watch Before Next Week", "url": "https://pennystocks.com/featured/2022/11/10/best-penny-stocks-to-buy-now-that-cpi-is-out-4-to-watch-before-next-week/", "time_published": "20221110T182905", "authors": ["J. Samuel"], "summary": "October CPI Data Is Out & These Penny Stocks Are Ripping Higher If you're looking for penny stocks to buy, the trend is your friend, as they say. Now that October's CPI inflation data is out, the market has reacted, and the bulls are trying to take control.", "banner_image": "https://pennystocks.com/wp-content/uploads/2022/08/penny-stocks-to-buy-powell-head-speech-jackson-hole-day.jpg", "source": "PennyStocks.com", "category_within_source": "n/a", "source_domain": "pennystocks.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.576289"}, {"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.999976"}, {"topic": "Earnings", "relevance_score": "0.77141"}, {"topic": "Technology", "relevance_score": "0.333333"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.17641, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GOOG", "relevance_score": "0.036091", "ticker_sentiment_score": "0.40786", "ticker_sentiment_label": "Bullish"}, {"ticker": "NVTA", "relevance_score": "0.282641", "ticker_sentiment_score": "0.177913", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "LGND", "relevance_score": "0.072108", "ticker_sentiment_score": "0.064605", "ticker_sentiment_label": "Neutral"}, {"ticker": "OABI", "relevance_score": "0.248561", "ticker_sentiment_score": "0.117114", "ticker_sentiment_label": "Neutral"}, {"ticker": "WFC", "relevance_score": "0.036091", "ticker_sentiment_score": "0.100591", "ticker_sentiment_label": "Neutral"}, {"ticker": "BLI", "relevance_score": "0.072108", "ticker_sentiment_score": "0.16061", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Why Cano Health Shares Are Trading Sharply Lower; Here Are 29 Stocks Moving Premarket - AbCellera Biologics  ( NASDAQ:ABCL ) , ADMA Biologics  ( NASDAQ:ADMA ) ", "url": "https://www.benzinga.com/news/22/11/29656483/why-cano-health-shares-are-trading-sharply-lower-here-are-29-stocks-moving-premarket", "time_published": "20221110T125844", "authors": ["Lisa Levin"], "summary": "Fast Radius, Inc. FSRD shares jumped 59% to $0.1619 in pre-market trading after dipping 40% on Wednesday. Fast Radius recently filed voluntary petitions for relief under Chapter 11. Digital Turbine, Inc. APPS rose 21.4% to $13.07 in pre-market trading after the company reported mixed Q2 results.", "banner_image": "https://cdn.benzinga.com/files/images/story/2022/11/10/image21.jpeg?optimize=medium&dpr=2&auto=webp&width=3840", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.166667"}, {"topic": "Energy & Transportation", "relevance_score": "0.166667"}, {"topic": "Technology", "relevance_score": "0.166667"}, {"topic": "Retail & Wholesale", "relevance_score": "0.166667"}, {"topic": "Financial Markets", "relevance_score": "0.95865"}, {"topic": "Manufacturing", "relevance_score": "0.166667"}, {"topic": "Earnings", "relevance_score": "0.999998"}, {"topic": "Real Estate & Construction", "relevance_score": "0.166667"}], "overall_sentiment_score": 0.041189, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "CANO", "relevance_score": "0.166935", "ticker_sentiment_score": "0.092182", "ticker_sentiment_label": "Neutral"}, {"ticker": "DM", "relevance_score": "0.111747", "ticker_sentiment_score": "-0.184546", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "RIVN", "relevance_score": "0.111747", "ticker_sentiment_score": "0.221299", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BMBL", "relevance_score": "0.111747", "ticker_sentiment_score": "-0.173509", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "HLGN", "relevance_score": "0.166935", "ticker_sentiment_score": "0.104629", "ticker_sentiment_label": "Neutral"}, {"ticker": "GOVX", "relevance_score": "0.111747", "ticker_sentiment_score": "-0.321504", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "VCSA", "relevance_score": "0.111747", "ticker_sentiment_score": "-0.17453", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "ABCL", "relevance_score": "0.111747", "ticker_sentiment_score": "0.233556", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DWAC", "relevance_score": "0.111747", "ticker_sentiment_score": "-0.194566", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "VRAX", "relevance_score": "0.166935", "ticker_sentiment_score": "-0.128991", "ticker_sentiment_label": "Neutral"}, {"ticker": "CLSK", "relevance_score": "0.111747", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "FSRD", "relevance_score": "0.166935", "ticker_sentiment_score": "0.253909", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BARK", "relevance_score": "0.111747", "ticker_sentiment_score": "0.233556", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "EGIO", "relevance_score": "0.111747", "ticker_sentiment_score": "0.046209", "ticker_sentiment_label": "Neutral"}, {"ticker": "ADMA", "relevance_score": "0.111747", "ticker_sentiment_score": "0.277005", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "APPS", "relevance_score": "0.111747", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ORGO", "relevance_score": "0.111747", "ticker_sentiment_score": "0.04016", "ticker_sentiment_label": "Neutral"}, {"ticker": "ASTS", "relevance_score": "0.111747", "ticker_sentiment_score": "-0.194566", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "BGS", "relevance_score": "0.111747", "ticker_sentiment_score": "-0.011743", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNES", "relevance_score": "0.166935", "ticker_sentiment_score": "-0.044422", "ticker_sentiment_label": "Neutral"}, {"ticker": "HUDI", "relevance_score": "0.166935", "ticker_sentiment_score": "0.134443", "ticker_sentiment_label": "Neutral"}, {"ticker": "MGNI", "relevance_score": "0.111747", "ticker_sentiment_score": "0.233556", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NRBO", "relevance_score": "0.111747", "ticker_sentiment_score": "-0.194566", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "MMAT", "relevance_score": "0.111747", "ticker_sentiment_score": "-0.199039", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "GOEV", "relevance_score": "0.111747", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "CPNG", "relevance_score": "0.111747", "ticker_sentiment_score": "0.221299", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ATXI", "relevance_score": "0.111747", "ticker_sentiment_score": "-0.014304", "ticker_sentiment_label": "Neutral"}, {"ticker": "OABI", "relevance_score": "0.166935", "ticker_sentiment_score": "0.118088", "ticker_sentiment_label": "Neutral"}]}, {"title": "Coupang, Rivian Automotive And Some Other Big Stocks Moving Higher In Today's Pre-Market Session - AbCellera Biologics  ( NASDAQ:ABCL ) , ADMA Biologics  ( NASDAQ:ADMA ) ", "url": "https://www.benzinga.com/news/22/11/29653727/coupang-rivian-automotive-and-some-other-big-stocks-moving-higher-in-todays-pre-market-session", "time_published": "20221110T112815", "authors": ["Lisa Levin"], "summary": "U.S. stock futures traded higher this morning. Here are some big stocks recording gains in today's pre-market trading session. Digital Turbine, Inc. APPS jumped 21.4% to $13.07 in pre-market trading after the company reported mixed Q2 results. Magnite, Inc.", "banner_image": "https://cdn.benzinga.com/files/images/story/2022/11/10/image-rivian_automotive.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.2"}, {"topic": "Technology", "relevance_score": "0.2"}, {"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Retail & Wholesale", "relevance_score": "0.2"}, {"topic": "Financial Markets", "relevance_score": "0.692272"}, {"topic": "Manufacturing", "relevance_score": "0.2"}, {"topic": "Earnings", "relevance_score": "0.980509"}, {"topic": "Real Estate & Construction", "relevance_score": "0.2"}], "overall_sentiment_score": 0.13251, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MGNI", "relevance_score": "0.259727", "ticker_sentiment_score": "0.390158", "ticker_sentiment_label": "Bullish"}, {"ticker": "ABCL", "relevance_score": "0.259727", "ticker_sentiment_score": "0.390158", "ticker_sentiment_label": "Bullish"}, {"ticker": "GOEV", "relevance_score": "0.259727", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ADMA", "relevance_score": "0.259727", "ticker_sentiment_score": "0.455289", "ticker_sentiment_label": "Bullish"}, {"ticker": "CPNG", "relevance_score": "0.259727", "ticker_sentiment_score": "0.3712", "ticker_sentiment_label": "Bullish"}, {"ticker": "NICE", "relevance_score": "0.259727", "ticker_sentiment_score": "0.398694", "ticker_sentiment_label": "Bullish"}, {"ticker": "RIVN", "relevance_score": "0.259727", "ticker_sentiment_score": "0.3712", "ticker_sentiment_label": "Bullish"}, {"ticker": "SLNA", "relevance_score": "0.259727", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "APPS", "relevance_score": "0.259727", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "OABI", "relevance_score": "0.380978", "ticker_sentiment_score": "0.221966", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ASTS", "relevance_score": "0.259727", "ticker_sentiment_score": "-0.329034", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Ocular Therapeutix And 2 Other Penny Stocks Insiders Are Aggressively Buying - Metacrine  ( NASDAQ:MTCR ) , OmniAb  ( NASDAQ:OABI ) ", "url": "https://www.benzinga.com/trading-ideas/long-ideas/22/11/29652969/ocular-therapeutix-and-2-other-penny-stocks-insiders-are-aggressively-buying", "time_published": "20221110T104127", "authors": ["Lisa Levin"], "summary": "The Dow Jones dipped by more than 600 points on Wednesday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects.", "banner_image": "https://cdn.benzinga.com/files/images/story/2022/11/10/image_3.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.108179"}, {"topic": "Energy & Transportation", "relevance_score": "0.333333"}, {"topic": "Technology", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.220328, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "LGND", "relevance_score": "0.120431", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "MTCR", "relevance_score": "0.455525", "ticker_sentiment_score": "0.353159", "ticker_sentiment_label": "Bullish"}, {"ticker": "AVA", "relevance_score": "0.120431", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "OABI", "relevance_score": "0.551295", "ticker_sentiment_score": "0.233878", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "OCUL", "relevance_score": "0.551295", "ticker_sentiment_score": "0.246426", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Ligand  ( LGND )  Beats on Q3 Earnings, Lags Sales, Ups '22 Outlook", "url": "https://www.zacks.com/stock/news/2015552/ligand-lgnd-beats-on-q3-earnings-lags-sales-ups-22-outlook", "time_published": "20221108T161700", "authors": ["Zacks Investment Research"], "summary": "Ligand (LGND) reports mixed third-quarter 2022 numbers, beating sales estimates but missing out on earnings. Share price rises as management lifts financial guidance for the year.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/71/1337.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}, {"topic": "Earnings", "relevance_score": "0.890401"}, {"topic": "Energy & Transportation", "relevance_score": "0.333333"}, {"topic": "Technology", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.08437, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "LGND", "relevance_score": "0.204936", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AVA", "relevance_score": "0.051774", "ticker_sentiment_score": "0.098515", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.103331", "ticker_sentiment_score": "0.091125", "ticker_sentiment_label": "Neutral"}, {"ticker": "OABI", "relevance_score": "0.396574", "ticker_sentiment_score": "0.082199", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRNA", "relevance_score": "0.051774", "ticker_sentiment_score": "-0.084541", "ticker_sentiment_label": "Neutral"}]}]}